Aug 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.

Aug 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The European Commission grants approval to Celltrion’s SteQeyma® (CT-P43), a biosimilar version of Stelara® (ustekinumab), for treating several chronic inflammatory disorders.

Galapagos reveals FDA approval of its IND application for the Phase 1/2 ATALANTA-1 trial of CD19 CAR-T therapy, GLPG5101, in non-Hodgkin lymphoma that has relapsed or is refractory.

Moderna, Inc. (NASDAQ:MRNA) reported that the European Commission (EC) has approved mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV), for marketing.

The company will commence a Phase III clinical trial aiming to investigate the effectiveness and safety of 9MW2821 in individuals with recurrent or metastatic cervical cancer (CC).

YolTech Therapeutics Administers First Patient Dose of YOLT-203 in Clinical Trial for Groundbreaking In Vivo Gene Editing Therapy for PH1.

we will proceed with a specific sequence example to explore how nucleotide information can be efficiently retrieved using Patsnap Bio.

FDA Approves Pfizer-BioNTech's Updated COVID-19 Vaccine for Ages 12 and Up; Grants Emergency Use for Ages 6 Months to 11 Years.

The European Commission has granted approval for BALVERSA® (erdafitinib) in treating adults with advanced or metastatic urothelial cancer.

This trial is investigating OMX-0407, a first-in-class, spectrum-selective SIK (salt-inducible kinase) inhibitor, in patients with advanced solid tumors.